<?xml version="1.0" encoding="UTF-8"?>
<p>On the other hand, using baricitinib is associated with an increased risk of developing severe infections due to opportunistic pathogens, especially if it is taken concomitantly with immunosuppressants such as corticosteroids [
 <xref rid="B74-pharmaceuticals-13-00096" ref-type="bibr">74</xref>]. Tuberculosis was identified in patients receiving baricitinib, and patients should be tested prior to and during therapy for latent tuberculosis infection. In addition, thrombosis, including deep venous thrombosis and pulmonary embolism, has been documented more than placebo in patients treated with baricitinib [
 <xref rid="B74-pharmaceuticals-13-00096" ref-type="bibr">74</xref>].
</p>
